Effect of polyphenols on glucose and lactate transport by breast cancer cells F. MartelM. GuedesE. Keating Review 20 April 2016 Pages: 1 - 11
Potential of breastmilk analysis to inform early events in breast carcinogenesis: rationale and considerations Jeanne MurphyMark E. ShermanKathleen F. Arcaro Review 23 April 2016 Pages: 13 - 22
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer Cameron P. CapperJosé M. LariosJames M. Rae Preclinical study 15 April 2016 Pages: 23 - 30
Apparent diffusion coefficient of breast cancer and normal fibroglandular tissue in diffusion-weighted imaging: the effects of menstrual cycle and menopausal status Jin You KimHie Bum SuhYoung Tae Bae Preclinical study 18 April 2016 Pages: 31 - 40
Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown Su-Hyeong KimEun-Ryeong HahmShivendra V. Singh Preclinical study 21 April 2016 Pages: 41 - 54
Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer Yukiko TabuchiMasafumi ShimodaShinzaburo Noguchi Preclinical Study 25 April 2016 Pages: 55 - 63
Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer Andrew R. GreenD. SoriaI. O. Ellis Preclinical study Open access 26 April 2016 Pages: 65 - 75
Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer A. ThakkarB. WangTan A. Ince Preclinical Study Open access 27 April 2016 Pages: 77 - 90
Prognostic impact of breast cancer subtypes in elderly patients E. S. BergenC. TichyR. Bartsch Clinical trial Open access 23 April 2016 Pages: 91 - 99
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14 Judith-Anne W. ChapmanDennis C. SgroiMichael N. Pollak Clinical Trial 26 April 2016 Pages: 101 - 108
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer Daniel RaysonSasha LupichukPenelope Bradbury Clinical trial 26 April 2016 Pages: 109 - 116
Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes Kristen S. PurringtonDaniel W. VisscherFergus J. Couch Epidemiology 15 April 2016 Pages: 117 - 131
Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL) Dawn L. HershmanLawrence H. KushiAlfred I. Neugut Epidemiology 16 April 2016 Pages: 133 - 143
Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer Christopher M. GallagherKenneth MoreBrian Barnett Epidemiology Open access 23 April 2016 Pages: 145 - 156
Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers Shani Paluch-ShimonEitan FriedmanBella Kaufman Epidemiology 25 April 2016 Pages: 157 - 165
Ethnic differences in the relationships between diabetes, early age adiposity and mortality among breast cancer survivors: the Breast Cancer Health Disparities Study Avonne E. ConnorKala VisvanathanMartha L. Slattery Epidemiology 26 April 2016 Pages: 167 - 178
Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study Roberto AgrestiElisabetta MeneghiniMilena Sant Epidemiology 27 April 2016 Pages: 179 - 189
Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis P. LavaudB. RousseauF. Goldwasser Brief Report 22 April 2016 Pages: 191 - 192
Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer Tisha M. FelderD. Phuong DoCharles L. Bennett Brief Report 27 April 2016 Pages: 193 - 200
Compliance with hormonal therapy Henry J. CarsonChirantan Ghosh Letter to the Editor 26 April 2016 Pages: 201 - 201